Biotech Values

[BTH]

2. CRIS is already encouraged by what they are observing in the first dosing cohort, which is the lowest starting dose. CEO noted they are surprised they are already starting to see some signals. CEO later disclosed that they are seeing AEs consistent with target suppression.

What do you take this to mean? "AEs consistent with target suppression". The Cohort1 is at 30mgs, Cohort2 at 60mgs. Should they have already seen AEs at the lowest dose level? I suppose if fhe drug is showing efficacy, and is doing its job, ok....but? And I am sure you know, 2 of the 3 patients in Cohort1 are multiple myeloma patients, refractory to two or more prior tx.